What is Eagle Pharmaceuticals, Inc. (EGRX) current stock price?

Eagle Pharmaceuticals, Inc. (EGRX) stock is trading at $0.25 with a 0% change.

What is the analyst consensus for EGRX stock?

No analyst coverage is currently available for EGRX.

What is the AI rating for EGRX stock?

Clear Report's AI rating for EGRX is N/A out of 100.

What is the market trend for EGRX stock?

Insufficient moving average data to determine the trend for EGRX.

Is EGRX stock volatile?

Volatility data for EGRX is not available.

What is the 52-week range for EGRX?

52-week range data for EGRX is not available.

EGRX (Eagle Pharmaceuticals, Inc.) Stock Analysis

Clear Report

EGRX

—

Loading EGRX

Fetching market data and analysis

EGRX

—

Loading EGRX

Fetching market data and analysis

EGRX

—

AI OVERVIEW

INVESTOR SUMMARY

1 of 6 unlocked

Overall Market Environment:

No analysis available.

Fundamental Expectations:

Detailed AI commentary for this dimension is available with a subscription.

Structural Position:

Detailed AI commentary for this dimension is available with a subscription.

Market Perception:

Detailed AI commentary for this dimension is available with a subscription.

Risk Environment:

Detailed AI commentary for this dimension is available with a subscription.

Stability & Signal Reliability:

Detailed AI commentary for this dimension is available with a subscription.

OVERALL AI-RATING

—

N/A

Score 0-100

Weak:

0-39

Balanced:

40-69

Strong:

70-100

AI score based on multi-state analysis

TICKER STATE SUMMARY

Market state:

—

Risk:

—

Confidence:

—

KEY DRIVERS

Severe price damage

Price damage data unavailable.

Relative underperformance

Relative performance data unavailable.

Elevated volatility

Volatility data unavailable.

STATE ALIGNMENT

1 of 3 unlocked

Market bias

bearishneutralbullish

—

MARKET REGIME

Trend

—vs SMA200

No dataPhase: N/A

Insufficient data to assess trend.

Relative performance

••vs S&P 500 (3M)

Status: ••Benchmark: ••

MOVE QUALITY

Momentum

RSI (14):••

RSI Change (5D):••

Liquidity

Rel Vol:••

Avg Vol (30D):••

RISK ENVIRONMENT

Volatility

ATR (14):••

ATR Percentile:••

Price damage

Drawdown vs 52W High:••

FUNDAMENTALS & MARKET PERCEPTION

Earning outlook

EPS Revision (3M):••

Guidance:••

Analyst confidence

Target trend (3M):••

Coverage:••

Financial Health

Cash runway:••

Net debt:••

Narrative momentum

Dominant theme:••

Insider Trading Activity

InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalForm

Analyst Rating Changes

DateActionAnalystRatingPrice Target Change

Loading EGRX

Fetching market data and analysis

EGRX (Eagle Pharmaceuticals, Inc.) Stock Analysis · AI Forecast | Clear Report

AI OVERVIEW

INVESTOR SUMMARY

1 of 6 unlocked

Overall Market Environment:

No analysis available.

Fundamental Expectations:

Detailed AI commentary for this dimension is available with a subscription.

Structural Position:

Detailed AI commentary for this dimension is available with a subscription.

Market Perception:

Detailed AI commentary for this dimension is available with a subscription.

Risk Environment:

Detailed AI commentary for this dimension is available with a subscription.

Stability & Signal Reliability:

Detailed AI commentary for this dimension is available with a subscription.

OVERALL AI-RATING

—

N/A

Score 0-100

Weak:

0-39

Balanced:

40-69

Strong:

70-100

AI score based on multi-state analysis

TICKER STATE SUMMARY

Market state:

—

Risk:

—

Confidence:

—

KEY DRIVERS

Severe price damage

Price damage data unavailable.

Relative underperformance

Relative performance data unavailable.

Elevated volatility

Volatility data unavailable.

STATE ALIGNMENT

1 of 3 unlocked

Market bias

bearishneutralbullish

—

MARKET REGIME

Trend

—vs SMA200

No dataPhase: N/A

Insufficient data to assess trend.

Relative performance

••vs S&P 500 (3M)

Status: ••Benchmark: ••

MOVE QUALITY

Momentum

RSI (14):••

RSI Change (5D):••

Liquidity

Rel Vol:••

Avg Vol (30D):••

RISK ENVIRONMENT

Volatility

ATR (14):••

ATR Percentile:••

Price damage

Drawdown vs 52W High:••

FUNDAMENTALS & MARKET PERCEPTION

Earning outlook

EPS Revision (3M):••

Guidance:••

Analyst confidence

Target trend (3M):••

Coverage:••

Financial Health

Cash runway:••

Net debt:••

Narrative momentum

Dominant theme:••

Insider Trading Activity

InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalForm

Analyst Rating Changes

DateActionAnalystRatingPrice Target Change